EGRP News Flash - February 8, 2011
Administrative Supplements for U.S. – China Biomedical Collaborative Research on Cancer, Allergy, Immunology, and Infectious Diseases Including HIV/AIDS and its Co-morbidities
On behalf of the National Cancer Institute (NCI) and the National Institute of Allergy and Infectious Diseases (NIAID), NCI’s Epidemiology and Genetics Research Program (EGRP) announces an opportunity for eligible National Institutes of Health (NIH) grantees to request administrative supplement support for active grants to enhance ongoing research efforts through collaborations with Chinese scientists under the new U.S. – China Program for Biomedical Research Cooperation.
Basic, translational, behavioral, clinical, preventive, or epidemiological research may be proposed under this program. Clinical trials of drugs, biologics, or diagnostics will NOT be supported through this program. Funding under this program can be used to support new, previously unforeseen research opportunities enhancing existing grants through collaboration between U.S. and Chinese scientists. The proposed research must be within the peer-reviewed scope of the NIH-supported parent grant. The NIH grant mechanisms eligible under this announcement are: active R01, P01, U19, U54, P30 (as pilot projects to the Developmental Core with no additional funding to infrastructure), and P50 awards.
Under this program, the NIH will support meritorious administrative supplements to existing NCI and NIAID grants, as well as any NIH grants in the area of HIV/AIDS and its co-morbidities. Up to $3,000,000 (total costs) will be available in Fiscal Year 2011. The National Science Foundation of China (NSFC) will provide complementary funds as new research grants to scientists who are current or former NSFC grantees to support the Chinese co-investigators for these collaborative projects.
Administrative supplements will be limited to 25 percent of the Institute Advisory Council-approved direct costs for the current budget year of the project or $100,000 direct costs, whichever is less. Awards will be for one year and the existing grant must have at least one year of active funding remaining at the time the supplement is awarded on September 30, 2011.
Applications are due by April 14, 2011. Inquiries and discussion of plans for responding to this opportunity are strongly encouraged.
Geraldina Dominguez, Ph.D.
Office of HIV and AIDS Malignancy
National Cancer Institute
31 Center Drive, Room 3A33, MSC 2440
Bethesda, MD 20852-2440
Telephone: (301) 496-3204
Julie A. Schneider, Ph.D.
Program Director, Office of China Cancer Programs
U.S. Embassy Beijing
No. 55 An Jia Lou Lu
Beijing 100600 P.R. China
Access the NIH Guide for Grants and Contracts for details: NOT-HG-11-006